The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain

INTRODUCTION: Once-weekly semaglutide has been associated with greater reductions in glycated hemoglobin (HbA1c) and body weight than sitagliptin and dulaglutide in the SUSTAIN 2 and 7 clinical trials, respectively. These trials also assessed the proportions of patients achieving treatment targets c...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Diabetes Ther
Главные авторы: Vidal, Josep, Malkin, Samuel J. P., Hunt, Barnaby, Martín, Virginia, Hallén, Nino, Javier Ortega, Francisco
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Healthcare 2020
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6995797/
https://ncbi.nlm.nih.gov/pubmed/31925724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00751-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы